Reardon, D. A., Sathornsumetee, S., Vredenburgh, J. J., Rich, J. N., Desjardins, A., Quinn, J. A., … Friedman, H. S. (2009). PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME. NEURO-ONCOLOGY, 11(2), 231–231.

Reardon, David A., Sith Sathornsumetee, James J. Vredenburgh, Jeremy N. Rich, Annick Desjardins, Jennifer A. Quinn, Alyssa Mathe, Sridharan Gururangan, Allen H. Friedman, and Henry S. Friedman. “PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME.” NEURO-ONCOLOGY 11, no. 2 (April 1, 2009): 231–231.

Reardon DA, Sathornsumetee S, Vredenburgh JJ, Rich JN, Desjardins A, Quinn JA, et al. PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME. NEURO-ONCOLOGY. 2009 Apr 1;11(2):231–231.

Reardon, David A., et al. “PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME.” NEURO-ONCOLOGY, vol. 11, no. 2, DUKE UNIV PRESS, Apr. 2009, pp. 231–231.

Reardon DA, Sathornsumetee S, Vredenburgh JJ, Rich JN, Desjardins A, Quinn JA, Mathe A, Gururangan S, Friedman AH, Friedman HS. PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME. NEURO-ONCOLOGY. DUKE UNIV PRESS; 2009 Apr 1;11(2):231–231.